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============

Type 2 diabetes mellitus (T2DM) is characterized by increased insulin insensitivity coupled with a progressive failure of pancreatic β-cells, resulting in a gradual loss of glycemic control and hyperglycemia \[[@CR1]\]. If uncontrolled, hyperglycemia can lead to diabetic complications, including microvascular (e.g., retinopathy) and macrovascular (e.g., myocardial infarction) complications \[[@CR2]\]. Globally, the prevalence of diabetes is increasing and it is estimated that 642 million people aged 20--79 years will have diabetes by 2040; of these people, 87--91% will have T2DM \[[@CR3]\]. In Japan, a national survey has shown that the prevalence of diabetes has increased from 8.9 million in 2007 to 10 million in 2016 \[[@CR4]\]. Specifically, a significant increase in the prevalence of T2DM has also been recorded in a cohort study \[[@CR5]\]; this study attributed the increase in T2DM to higher rates of obesity and reduced physical activity levels \[[@CR5]\].

Treatment for T2DM is focused on the management of hyperglycemia and reducing the levels of glycated hemoglobin (HbA~1c~) \[[@CR6]\]; the reduction in HbA~1c~ is associated with a reduction in the risk of diabetic complications \[[@CR2], [@CR7]\]. In Japan, the main HbA~1c~ target set by the Japanese Diabetes Society is \< 7% (53.0 mmol/mol), which was established from the perspective of preventing complications \[[@CR8]\]. However, despite the wide range of treatments available, a recent survey has shown that 47% of patients with T2DM in Japan do not achieve the recommended HbA~1c~ goal \[[@CR9]\]. In addition, patients with a higher body mass index (BMI) were less likely to achieve the HbA~1c~ target than patients with a lower BMI \[[@CR9]\]. Weight gain is also a known side effect of many oral antidiabetic drugs (OADs) and insulins used to treat T2DM, and may be associated with an increased risk of cardiovascular disease \[[@CR10], [@CR11]\].

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are a class of drugs that act by increasing glucose-dependent insulin secretion, preserving β-cell function, suppressing glucagon levels, and slowing gastric emptying \[[@CR12], [@CR13]\]. Unlike other therapies in T2DM, treatment with GLP-1 RA is typically associated with weight loss \[[@CR14]--[@CR17]\] and may also reduce cardiovascular risk \[[@CR18]\]. In Japan, GLP-1 RAs are increasingly prescribed for the treatment of T2DM and several studies have demonstrated the efficacy and safety of GLP-1 RAs in the Japanese population \[[@CR19]--[@CR23]\]. Studies have also shown that GLP-1 RAs are more effective in Japanese/Asian populations when compared with European populations \[[@CR24], [@CR25]\], and are typically administered at a lower dose in the Japanese population \[[@CR26]\]. This is because T2DM in Asian patients is primarily characterized by higher β-cell dysfunction, rather than insulin resistance \[[@CR27]\], and GLP-1 RAs have a proven ability to improve β-cell function \[[@CR28]\]. Therefore, GLP-1 RAs are a favorable choice of therapy for this population. Japanese patients with T2DM are also generally less obese than their European counterparts and the exposure of a fixed dose GLP-1 RA will be greater in lighter patients.

Semaglutide once-weekly (QW) is a novel GLP-1 analogue administered at a 0.5 or 1.0 mg dose. The efficacy and safety of semaglutide QW has been assessed across the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program, which included two multicenter, head-to-head trials comparing semaglutide QW with exenatide QW or dulaglutide QW. In SUSTAIN 3, treatment with semaglutide QW provided significant reductions in HbA~1c~ and weight when compared with exenatide QW, both as an add-on to 1--2 OADs \[metformin and/or sulfonylurea (SU) and thiazolidinedione (TZD)\] \[[@CR29]\]. In SUSTAIN 7, semaglutide QW also provided significant reductions in HbA~1c~ and weight when compared with dulaglutide QW, both as an add-on to metformin \[[@CR30]\]; however, no Japanese patients were included in this trial.

The efficacy and safety of semaglutide QW in a Japanese population with T2DM were demonstrated in two recent trials. One trial compared semaglutide QW (0.5 and 1.0 mg) as monotherapy with sitagliptin 100 mg once-daily (QD) \[[@CR31]\]. After 30 weeks, both doses of semaglutide QW demonstrated significant reductions in HbA~1c~ and weight compared with sitagliptin 100 mg QD; the safety profile was also comparable to other GLP-1 RAs. Semaglutide QW (0.5 and 1.0 mg) was also assessed in a 56-week trial of patients who had poor glycemic control on diet and exercise or one OAD \[[@CR32]\]. The addition of semaglutide QW was associated with significant improvements in HbA~1c~ and weight when compared with the addition of another OAD.

Following the recent introduction of health technology appraisal (HTA) in Japan and the increasing amount of treatment options available to patients with T2DM, decision-makers need to assess the relative clinical benefits and risks of each treatment to make recommendations on their use within a limited budget. The availability of such comparative clinical data can also be used for cost-effectiveness analyses in Japan in the context of HTA. In the absence of head-to-head trials between semaglutide QW and other GLP-1 RAs in a Japanese population, a network meta-analysis (NMA) was performed. The objective was to assess the relative efficacy and safety of semaglutide QW vs GLP-1 RAs in Japanese patients, with a specific focus on the comparison between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW; dulaglutide is the latest QW GLP-1 RA in Japan (only available as a 0.75 mg QW dose) and semaglutide 0.5 mg QW is the expected maintenance dose for the Japanese population.

Methods {#Sec2}
=======

Systematic Review {#Sec3}
-----------------

A systematic review (SR) was performed in accordance with PRISMA guidelines \[[@CR33]\] to identify trials of GLP-1 RAs in Japanese patients with T2DM. Searches of MEDLINE^®^, Embase, and the Cochrane Library were performed via Ovid on April 5, 2016, with updates occurring on October 3, 2016 and August 16, 2017. Searches of conference proceedings were also carried out for the European Association for the Study of Diabetes (EASD; 2014--2016), the International Society for Pharmacoeconomics and Outcomes Research (ISPOR; 2014--2017), the International Diabetes Federation (IDF; 2013 and 2015), and the American Diabetes Association (ADA) Scientific Sessions (2014--2017). The search results were then screened against the SR eligibility criteria to generate a list of potential studies to include in the NMA (Table S1). As the eligibility criteria of the SR were restricted to studies published in English, a supplementary search of four Japanese language databases (Japan Pharmaceutical Information Center, Japan Science and Technology Information Aggregator, J-GLOBAL, and Igaku Chuo Zasshi) was conducted to ensure all potentially relevant studies had been identified.

Citations of interest were identified by one reviewer and verified by a second independent reviewer on the basis of title and abstract. Full publications were obtained for all citations of interest and were assessed by one reviewer and verified by a second independent reviewer. Any uncertainties were resolved through discussion between reviewers. Data were then extracted into an Excel spreadsheet by one reviewer and checked by a second reviewer. All included references were assessed for risk of bias using a seven-criteria checklist as approved by the National Institute of Health and Care Excellence (NICE) \[[@CR34]\].

NMA Methodology {#Sec4}
---------------

An NMA was performed to compare the efficacy and safety of GLP-1 RAs in Japanese patients, where the primary intervention of interest was semaglutide 0.5 mg QW and the comparators of interest were all other licensed doses of GLP-1 RAs in Japan---liraglutide QD, dulaglutide QW, exenatide twice-daily (BID), exenatide QW, and lixisenatide QD. In order to reduce variability between populations in different trials, the population of interest was aligned to the two Japanese SUSTAIN trials of semaglutide QW \[NN9535-4091 trial (NCT02207374; now available as a full-text publication, Kaku et al. \[[@CR32]\]) and NN9535-4092 (NCT02254291; now available as a full-text publication, Seino et al. \[[@CR31]\])\]. Therefore, while trials investigating a broader population were eligible for inclusion in the SR (Table S1), only trials investigating semaglutide QW or other licensed doses of GLP-1 RAs in Japan and in Japanese populations who have previously received 0--1 OADs were considered for further analysis.

The feasibility of performing an NMA at two time points (30 and 56 weeks), based on the study durations of the two Japanese SUSTAIN trials, was examined. All trials identified in the SR were examined for data on at least one outcome of interest at approximately 30 weeks (duration of the NN9535-4092 trial \[[@CR31]\]) and 56 weeks (duration of the NN9535-4091 trial \[[@CR32]\]), and the ability to form a best-case connected network was assessed. The feasibility of generating evidence networks for each of the 20 outcomes of interest (Table S1) was next examined; the outcomes of interest included HbA~1c~ outcomes \[e.g., change from baseline, proportion of patients achieving a level \< 7% (53 mmol/mol)\], weight, BMI, systolic blood pressure (SBP), fasting plasma glucose (FPG), postprandial plasma glucose ,and safety outcomes (including the incidence of overall hypoglycemia).

The analysis of continuous outcomes (e.g., change from baseline in HbA~1c~) was performed using a normal likelihood, identity link, single parameter model (based on arm-level data), or a shared parameter model, which allows for a single coherent synthesis when outcome data is reported at both the arm level and trial level. For dichotomous outcomes, a binomial likelihood, logit link model was used for efficacy outcomes \[e.g., proportion of patients achieving a HbA~1c~ level \< 7% (53 mmol/mol)\], while a binomial likelihood, cloglog link model was used for safety outcomes (e.g. ,incidence of overall hypoglycemia). All analyses were performed using a fixed effects (FE) model; the FE model provided a better model fit compared with the random effects (RE) model in terms of deviance information criterion and residual deviance.

The NMA models were implemented using WinBUGS software (MRC Biostatistics Unit, Cambridge, UK) \[[@CR35]\] and employed a Bayesian framework with the inclusion of vague prior distributions. Three Markov Monte Carlo chains were used, starting from different initial values of selected unknown parameters. Convergence for all models were assessed by analyzing history and density plots, and Brooks--Gelman--Rubin diagnostic plots \[[@CR36]\]. In addition, autocorrelation plots were assessed to detect the presence of autocorrelation in the chains. Following this, model convergence inferences were made from data obtained by sampling for a further 20,000 iterations.

For continuous outcomes, a mean treatment effect with an associated 95% credible interval (CrI) is estimated and the treatment difference (95% CrI) for semaglutide 0.5 mg QW vs comparator is presented. For dichotomous outcomes, an odds ratio (OR) with an associated 95% CrI is calculated for semaglutide 0.5 mg QW vs comparator. A difference between semaglutide 0.5 mg QW and a comparator is assumed to only exist when the 95% CrI does not include the null value for treatment differences, or one for ORs.

Finally, this article does not contain any new studies with human or animal subjects performed by any of the authors.

Results {#Sec5}
=======

Identified Publications {#Sec6}
-----------------------

A total of 2387 unique citations of potential interest were identified in the electronic search and nine citations were identified in the supplementary searches. Data on two studies (NN9535-4091 and NN9535-4092) were provided by Novo Nordisk in the form of clinical trial summary reports (CSRs) ahead of publication. Both studies are now publicly available as full-text publications \[[@CR31], [@CR32]\]; henceforth, the NN9535-4091 trial is also referred to as "Kaku 2018\" \[[@CR32]\] and the NN9535-4092 trial is also referred to as "Seino 2018" \[[@CR31]\]. Of these, 33 publications relating to 29 unique randomized controlled trials (RCTs) were considered to meet the inclusion criteria for the SR (the overall flow of studies across the SR and supplementary searches is shown in a PRISMA diagram in Fig. S1). In total, ten trials were considered to be the most relevant for the NMA.

These ten trials were examined for time points for which data were available for at least one outcome of interest. Six trials reported on an outcome of interest between 23 and 30 weeks (approximately 6 months); however, an analysis at 30 weeks based on the duration of Seino 2018 \[[@CR31]\] was not feasible, as no connected network between semaglutide and dulaglutide could be formed. The analysis at 56 weeks based on the duration of Kaku 2018 \[[@CR32]\] was possible as three additional trials reported on an outcome of interest at 52 weeks (considered sufficiently close to 56 weeks to allow comparison) and formed a connected network with Kaku 2018 \[[@CR32]\].

Within the four trials included in the analysis at 52--56 weeks, the intervention of interest (semaglutide 0.5 mg QW) and two comparators of interest (dulaglutide QW and liraglutide QD) were assessed. Two trials included liraglutide 0.9 mg QD, while one trial included dulaglutide 0.75 mg QW; the dosages of both GLP-1 RAs represent the highest dose available in Japan \[[@CR23], [@CR37]\]. A lower dose of liraglutide (liraglutide 0.6 mg QD) was also reported in one trial. No trials assessing exenatide (BID or QW) or lixisenatide QD were eligible for inclusion in the NMA.

The study design and patient characteristics of the four trials included in the analysis at 52--56 weeks were generally similar and suitable for comparison within an evidence network (Table [1](#Tab1){ref-type="table"}). All four studies were multicenter phase 3 trials conducted in Japan. The risk of bias (based on the NICE checklist) across the four trials was considered low (Fig. S2); however, Odawara 2016 \[[@CR23]\] and Seino 2011 \[[@CR38]\] were both double-blind trials, while Kaku 2016 and Kaku 2018 \[[@CR22], [@CR32]\] were both open-label trials. In line with the population of interest, all trials enrolled adult populations (≥ 20 years) with T2DM who had not received any treatments (*n* = 2) or had received one OAD (*n* = 2). The mean age of trial populations ranged from 57.6 to 59.7 years, and 18.5--36.0% of patients were female. The mean weight of the patients was also similar across the trials and ranged from 65.8 to 71.6 kg, while the mean BMI ranged from 24.9 to 26.5 kg/m^2^. The characteristic with the greatest variability was the mean disease duration, which ranged from 6.6 to 10.3 years across the trials. However, the trials recruited patients of a similar level of disease severity as indicated by the baseline HbA~1c~ levels; all trials enrolled patients with a HbA~1c~ value of \> 7% (53.0 mmol/mol), which is suggestive of inadequate control as per the ADA guidelines, and the mean baseline HbA~1c~ ranged from 8.09% to 8.82% (64.9--72.9 mmol/mol).Table 1Overview of design and baseline characteristics of trials included in the NMATrialNumber of patients randomized and exposedRandomized treatmentBackground therapyProportion of patients receiving one OAD (%)Female, *n* (%)Mean age, years (SD)Mean baseline weight, kg (SD)Mean baseline HbA~1c~, % (SD)Mean baseline duration of diabetes, years (SD)Mean baseline BMI, kg/m^2^ (SD)Kaku 2016 \[[@CR22]\]\
Open-label, parallel trial\
Japan240LIRA starting dose 0.3 mg QD changing to 0.9 mg QDPretrial OAD240 (100)58 (24)59.6 (11.6)69.4 (14.2)8.1 (0.8)7.80 (5.77)25.7 (4.2)120LIRA starting dose 0.3 mg QD changing to 0.9 mg QD + additional OADPretrial OAD + additional OAD120 (100)40 (33)59.2 (10.2)68.2 (13.6)8.1 (0.8)8.47 (6.55)25.5 (3.7)Kaku 2018 \[[@CR32]\]\
Phase 3a, open-label, active-controlled, parallel trial\
Japan239SEMA 0.5 mg QWSU, glinide, α-GI, or TZDNA73 (30.5)58.0 (10.6)71.0 (15.4)8.04 (0.89)8.12 (6.01)26.25 (4.80)241SEMA 1.0 mg QWSU, glinide, α-GI, or TZDNA67 (27.8)58.7 (10.2)71.7 (15.9)8.14 (0.96)9.35 (6.50)26.42 (4.71)120Additional OAD (either of SU, glinide, α-GI, or TZD)SU glinide, α-GI, or TZDAll31 (25.8)59.2 (10.1)72.2 (14.9)8.10 (0.89)9.27 (6.99)26.73 (4.56)Odawara 2016 \[[@CR23]\]\
Phase 3, double blind, parallel trial\
Japan280DULA 0.75 mg QWNoneNA52 (19)57.2 (9.6)71.3 (12.5)8.15 (0.77)6.8 (5.6)25.6 (3.6)137LIRA starting dose 0.3 mg QD changing to 0.9 mg QDNoneNA24 (18)57.9 (10.4)70.2 (12.5)8.08 (0.89)6.3 (6.0)25.5 (3.5)Seino 2011 \[[@CR38]\]\
Double-blind, parallel trial\
Japan88LIRA starting dose 0.3 mg QD changing to 0.9 mg QDSU88 (100)29 (33)61.3 (11)64.5 (12.0)8.61 (0.78)11.6 (7.7)24.4 (3.8)88LIRA starting dose 0.3 mg QD changing to 0.6 mg QDSU88 (100)35 (40)59.1 (10.3)66.2 (12.0)9.0 (0.91)9.3 (5.8)25.3 (3.6)88PlaceboSU88 (100)31 (35)58.6 (9.7)66.8 (13.7)8.85 (0.99)10.1 (7.3)24.9 (4.0)*α-GI* α-glucosidase inhibitor, *BMI* body mass index, *DULA* dulaglutide, *HbA*~*1c*~ glycated hemoglobin, *LIRA* liraglutide, *NA* not applicable, *OAD* oral antidiabetic drug, *QD* once-daily, *QW* once-weekly, *SD* standard deviation, *SEMA* semaglutide, *SU* sulfonylurea, *TZD* thiazolidinedione

Trial Data and Evidence Networks {#Sec7}
--------------------------------

For the analysis at 52--56 weeks, outcome-specific evidence networks were possible for 7 of the 20 outcomes of interest assessed for feasibility. It should be noted that it was not possible to conduct NMAs on the majority of the safety outcomes included in the SR eligibility criteria (Table S1). This was due to a paucity of data, which precluded the ability to generate connected networks with semaglutide QW. All four trials reported data on HbA~1c~ \[change from baseline and percentage achieving a HbA~1c~ level \< 7.0% (53 mmol/mol)\] and FPG (change from baseline; Table S2) at 52--56 weeks and were used to construct an evidence network to compare these outcomes for semaglutide 0.5 mg QW, dulaglutide 0.75 mg QW, and liraglutide 0.6 and 0.9 mg QD (Fig. [1](#Fig1){ref-type="fig"}); in this network, an additional OAD \[metformin, SU, α-glucosidase inhibitor (α-GI), TZD, dipeptidyl peptidase-4 (DPP-4) inhibitor, or a glinide\] and placebo are essential secondary comparators. Although not a primary intervention of interest, semaglutide 1.0 mg QW was included in the network as it was assessed alongside semaglutide 0.5 mg QW in Kaku 2018 \[[@CR32]\]; the results for semaglutide 0.5 mg QW vs semaglutide 1.0 mg QW are presented to aid interpretation. Three trials reported data for the change from baseline in SBP and weight, and the overall incidence of hypoglycemia at 52--56 weeks (Table S2). It should be noted that while the overall incidence of hypoglycemia was recorded in the NN9535-4091 trial, these data are not published in Kaku 2018 \[[@CR32]\]; for transparency, these data have now been made available in Table S2. As Seino et al. \[[@CR38]\] did not report any data for these outcomes, liraglutide 0.6 mg QD is absent from the evidence network (Fig. [1](#Fig1){ref-type="fig"}). An additional evidence network was also possible for these three trials for the incidence of nocturnal hypoglycemia; however, the model was unstable and failed to converge because of the low number of events reported in the trials.Fig. 1Evidence networks for **a** HbA~1c~ (change from baseline and percentage achieving a HbA~1c~ level \< 7.0% (53 mmol/mol) and FPG (change from baseline), **b** SBP, weight (both change from baseline), and hypoglycemia (overall incidence). HbA~1c~ glycated hemoglobin, FPG fasting plasma glucose, OAD oral antidiabetic drug, QD once-daily, QW once-weekly, SBP systolic blood pressure

NMA Results {#Sec8}
-----------

The results of the NMA for the change from baseline in HbA~1c~ and FPG are presented as treatment differences in Fig. [2](#Fig2){ref-type="fig"} (the absolute differences from baseline are shown in Table S3). This analysis demonstrated that when compared with dulaglutide 0.75 mg QW, semaglutide 0.5 mg QW is associated with a significant 0.61% (95% CrI − 0.92, − 0.30) reduction in HbA~1c~ (absolute reduction − 2.00% vs − 1.39%) and a significant 1.26 mmol/L (95% CrI − 1.78, − 0.74) reduction in FPG (absolute reduction − 3.42 vs − 2.16 mmol/L). The treatment differences compared with liraglutide 0.6 and 0.9 mg QD were also significant in favor of semaglutide 0.5 mg QW. An additional analysis of glycemic control showed that the likelihood of achieving a HbA~1c~ level \< 7.0% (53.0 mmol/mol) was comparable between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW \[OR 2.01 (95% CrI 0.91, 4.49), Table [2](#Tab2){ref-type="table"}\]; the likelihood of achieving this outcome was 78.4% and 64.3% for semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW, respectively (Table S3). However, patients were found to be significantly more likely to achieve a HbA~1c~ level \< 7.0% (53.0 mmol/mol) with semaglutide 0.5 mg QW compared with liraglutide 0.6 mg and 0.9 mg QD (Table [2](#Tab2){ref-type="table"}). Overall, semaglutide 1.0 mg QW was associated with the greatest improvements in both HbA~1c~ and FPG.Fig. 2Forest plots of the NMA results (semaglutide 0.5 mg QW vs comparator) for the change from baseline in HbA~1c~ and FPG. Treatment differences are considered significant when the 95% CrI excludes the null value. CrI credible interval, FPG fasting plasma glucose, HbA~1c~ glycated hemoglobin, NMA network meta-analysis, QD once-daily, QW once-weekly Table 2NMA results (semaglutide 0.5 mg QW vs comparator) for percentage of patients achieving a HbA~1c~ level of \< 7% (53 mmol/mol) and the incidence of overall hypoglycemiaComparatorOdds ratio (95% CrI)---semaglutide 0.5 mg QW vs comparatorPercentage of patients achieving a HbA~1c~ level of \< 7% (53 mmol/mol) Dulaglutide 0.75 mg QW2.01 (0.91, 4.49) Liraglutide 0.6 mg QD**10.64 (3.96, 29.36)** Liraglutide 0.9 mg QD**2.85 (1.45, 5.62)** Semaglutide 1.0 mg QW**0.49 (0.27, 0.85)**Incidence of overall hypoglycemia Dulaglutide 0.75 mg QW2.99 (0.21, 40.09) Liraglutide 0.9 mg QD3.11 (0.31, 30.35) Semaglutide 1.0 mg QW0.75 (0.47, 1.18)Bold values indicate odds ratios where the associated 95% CrI excludes 1*CrI* credible interval, *HbA*~*1c*~ glycated hemoglobin, *NMA* network meta-analysis, *QD* once-daily, *QW* once-weekly

The NMA results for the change from baseline in weight (Fig. [3](#Fig3){ref-type="fig"}) demonstrated that semaglutide 0.5 mg QW is associated with a significant 1.45 kg (95% CrI − 2.65, − 0.25) reduction in weight compared with dulaglutide 0.75 mg QW (absolute reduction − 1.62 vs − 0.17 kg; Table S3). The treatment difference compared with liraglutide 0.9 mg QD was also significant in favor of semaglutide 0.5 mg QW. The analysis of the change from baseline in SBP (Fig. [3](#Fig3){ref-type="fig"}) was associated with a higher level of uncertainty as shown by the wide 95% CrIs. However, a significant reduction in SBP of 5.03 mmHg (95% CrI − 9.29, − 0.79) with semaglutide 0.5 mg QW compared with dulaglutide 0.75 mg QW was still observed (absolute difference from baseline − 3.60 vs 1.45 mmHg; Table S3). Semaglutide 1.0 mg QW demonstrated the greatest improvements in weight and SBP.Fig. 3Forest plots of the NMA results (semaglutide 0.5 mg QW vs comparator) for the change from baseline in weight and SBP. Treatment differences are considered significant when the 95% CrI excludes the null value. CrI credible interval, FPG fasting plasma glucose, HbA~1c~ glycated hemoglobin, NMA network meta-analysis, QD once-daily, QW once-weekly, SBP systolic blood pressure

Generally, the incidence of overall hypoglycemia was low across the three trials included in the NMA of this outcome (Table S2). Overall, the results of the NMA did not reveal any significant difference in the incidence of overall hypoglycemia between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW \[OR 2.99 (95% CrI 0.21, 40.09)\] or liraglutide 0.9 mg QD \[OR 3.11 (95% CrI 0.31, 30.35), Table [2](#Tab2){ref-type="table"}\]; the incidence was 5.2%, 1.8%, and 1.7% for semaglutide 0.5 mg QW, dulaglutide 0.75 mg QW, and liraglutide 0.9 mg QD, respectively (Table S3). The risk of overall hypoglycemia was also similar between semaglutide 0.5 mg QW and semaglutide 1.0 mg QW.

Discussion {#Sec9}
==========

The objective of this study was to assess the relative efficacy and safety of semaglutide 0.5 mg QW vs GLP-1 RAs in Japanese patients, with a specific focus on the comparison between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW. Overall, semaglutide 0.5 mg QW was associated with significant reductions from baseline in HbA~1c~, weight, SBP, and FPG, compared with dulaglutide 0.75 mg QW. In addition, semaglutide 0.5 mg QW achieved significant reductions from baseline in HbA~1c~ and FPG vs both liraglutide 0.6 and 0.9 mg QW, and a significant reduction in weight vs liraglutide 0.9 mg QW (liraglutide 0.6 mg QD was not available for comparison). Furthermore, semaglutide 0.5 mg QW was associated with significantly higher odds of achieving a HbA~1c~ level \< 7% (53.0 mmol/mol) compared with liraglutide 0.6 mg and 0.9 mg QD.

To our knowledge, this is the first NMA comparing semaglutide QW with other GLP-1 RAs in a Japanese population. However, the results of this NMA can be compared with the recent head-to-head, multicenter (Asia, Europe, and the USA), clinical trial SUSTAIN 7, which assessed semaglutide QW and dulaglutide QW, both as an add-on to metformin \[[@CR30]\]. The direction of effect for HbA~1c~ and weight demonstrated between semaglutide 0.5 mg QW and dulaglutide 0.75 mg QW in our analysis is broadly consistent with the data reported in SUSTAIN 7. In SUSTAIN 7 (which did not include any Japanese patients), semaglutide 0.5 mg QW demonstrated a statistically significant reduction in HbA~1c~ (− 1.5% vs − 1.1%) and weight (− 4.6 vs − 2.3 kg) compared with dulaglutide 0.75 mg at 40 weeks. This equates to a treatment difference of − 0.4% for HbA~1c~ and − 2.3 kg for weight (both in favor of semaglutide 0.5 mg QW), which are similar to the treatment differences estimated in our NMA at 52--56 weeks \[− 0.61% (95% CrI − 0.92, − 0.30) and − 1.45 kg (95% CrI − 2.65, − 0.25), respectively\]. SUSTAIN 7 also demonstrated that more patients achieved a HbA~1c~ level ≤ 7% (53.0 mmol/mol) with semaglutide 0.5 mg QW compared with dulaglutide 0.75 mg QW (69% vs 52%). In our analysis, semaglutide 0.5 mg QW was associated with an OR of 2.01 vs dulaglutide 0.75 mg QW for the proportion of patients achieving a HbA~1c~ level \< 7% (53.0 mmol/mol), thereby corroborating what was observed in SUSTAIN 7; however, as the 95% CrI included 1, statistical significance could not be concluded.

Overall, our analysis provides a robust assessment of the efficacy of semaglutide QW across five outcomes compared with dulaglutide QW and liraglutide QD. In contrast, it was only possible to provide estimates for one safety outcome (incidence of overall hypoglycemia), which limits the ability to make any definitive conclusions from our study on the relative safety of semaglutide QW compared with other GLP-1 RAs. However, the two recent Japanese trials of semaglutide QW have demonstrated that its safety profile is comparable to other GLP-1 RAs \[[@CR31], [@CR32]\]. Our analysis of the incidence of overall hypoglycemia is in agreement with these findings, as no significant differences for semaglutide 0.5 mg QW vs dulaglutide 0.75 mg QW or liraglutide 0.9 mg QD were detected. The NMAs were also subject to additional limitations. Although an SR and supplementary Japanese-specific searches were conducted to identify relevant trials, only four trials were available for the analysis at 52--56 weeks. Consequently, the direct comparisons within the evidence network were supported by data from only one trial each. In addition, while the overall risk of bias across the trials included in the analyses was low, the highest risk was associated with study blinding due to the presence of two open-label trials. The absence of double-blinding may be considered a limitation as this can potentially introduce performance bias into the NMA \[[@CR39]\].

Analysis of a few secondary outcomes assessed may have also been limited by poor reporting or low event rates. The overall incidence of hypoglycemia was low across the trials, which may have contributed to greater uncertainty in the analysis. Hypoglycemic episodes are often underreported by patients, which may be due to reasons such as fear of being judged, losing their job or driving license, and unawareness of nocturnal events \[[@CR40], [@CR41]\]. In addition, studies often report the number of patients with hypoglycemic events, rather than the actual frequency of events \[[@CR41]\]. Furthermore, non-severe events are not always reported in trials. Patients may not consider such mild events as important enough to mention to their doctor \[[@CR41], [@CR42]\]. Greater uncertainty was also observed in the analysis of SBP, when compared to the analysis of HbA~1c~, FPG, and weight. The measurement of SBP is known to be variable and values can differ for the same patient throughout the day. In addition, there are often patient-, device-, and procedure-related inaccuracies in the way that blood pressure is monitored \[[@CR43]\]. Together, these may have contributed to the uncertainty present in our analysis of SBP. Despite this, a significant difference in the reduction of SBP from baseline with semaglutide 0.5 mg QW compared with dulaglutide 0.75 mg QW was still observed.

Conclusion {#Sec10}
==========

Our analysis suggests that semaglutide 0.5 mg QW provides greater efficacy compared with dulaglutide 0.75 mg QW in the treatment of Japanese patients with T2DM. Statistically significant improvements for semaglutide 0.5 mg QW vs dulaglutide 0.75 mg QW were found for HbA~1c~, weight, SBP, and FPG. In the absence of head-to-head trials between semaglutide QW and other GLP-1 RAs in a Japanese population, this NMA provides an estimate of the relative efficacy of semaglutide QW. Following the recent introduction of HTA in Japan, and the increasing amount of treatment options available for T2DM, these data provide valuable evidence for decision-making and cost-effectiveness analyses.
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